Neurophet Supplies Brain Imaging Software to Raffles Medical in Singapore
Neurophet announced in a press release that it has signed a supply agreement with Raffles Medical in Singapore for its neurodegenerative brain imaging analysis software, Neurophet AQUA.
Neurophet AQUA performs quantitative analysis of brain MRI scans, allowing clinicians to assess brain atrophy and white matter degeneration. The software measures structural changes associated with neurodegenerative diseases such as Alzheimer's disease and vascular dementia. It generates analysis reports tailored to each patient.
Raffles Medical is part of Raffles Medical Group, which operates more than 100 clinics across Singapore and Asia. The clinics are connected to Raffles Hospital and Raffles Specialist Centres, providing access to diagnostic and specialist services.
Neurophet has previously collaborated with local institutions including the Dementia Research Centre at Nanyang Technological University, the National University of Singapore, and Singapore General Hospital. The company develops AI based diagnostic and treatment support tools for brain disorders, with products including Neurophet SCALE PET, Neurophet tES/TMS LAB, and Neurophet AQUA AD.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice Operations Oct 15 Study Tracks 270 Million Clinical AI Queries on OpenEvidence Oct 15 OpenAI Offers US University Labs Free GPT-Rosalind AccessLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Anthropic Opens Singapore Office and Signs AI Safety Agreement
Anthropic to Open Singapore Office in October
Brainomix and Pulmonary Fibrosis Foundation Partner on AI Lung Imaging Research
Singapore Launches Three AI Safety Initiatives
Healthleap Raises $38 Million for Hospital Risk Screening AI
Daily AI Brief: the AI news that matters, in your inbox.